Clinical and prognostic significance of MYH11 in lung cancer

Nie, Mengjun; Pan, Xiaoting; Tao, Heyun; Xu, Meng‐Jun; Liu, Shenlin; Sun, Wei; Wu, Jian; Zou, Xi

doi:10.3892/ol.2020.11478

Cited by 21 publications

(22 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It functions by stimulating effector cell functions and encouraging antitumor CD8+ T cells to enter tumors, aiding in the establishment of anti-tumoral memory ( Skeate et al, 2020 ). MYH11 encodes a protein that participates in muscle contraction through the hydrolysis of adenosine triphosphate; its expression levels are downregulated in several types of cancers ( Alhopuro et al, 2008 ; Nie et al, 2020 ). NRXN1 encodes a transmembrane protein that functions as a cell adhesion molecule in synaptic transmission ( Reissner et al, 2008 ).…”

Section: Discussionmentioning

confidence: 99%

Identification of Tumor Microenvironment-Related Prognostic Genes in Sarcoma

et al. 2021

View full text Add to dashboard Cite

AimImmune cells that infiltrate the tumor microenvironment (TME) are associated with cancer prognosis. The aim of the current study was to identify TME related gene signatures related to the prognosis of sarcoma (SARC) by using the data from The Cancer Genome Atlas (TCGA).MethodsImmune and stromal scores were calculated by estimation of stromal and immune cells in malignant tumor tissues using expression data algorithms. The least absolute shrinkage and selection operator (lasso) based cox model was then used to select hub survival genes. A risk score model and nomogram were used to predict the overall survival of patients with SARC.ResultsWe selected 255 patients with SARC for our analysis. The Kaplan–Meier method found that higher immune (p = 0.0018) or stromal scores (p = 0.0022) were associated with better prognosis of SARC. The estimated levels of CD4+ (p = 0.0012) and CD8+ T cells (p = 0.017) via the tumor immune estimation resource were higher in patients with SARC with better overall survival. We identified 393 upregulated genes and 108 downregulated genes (p < 0.05, fold change >4) intersecting between the immune and stromal scores based on differentially expressed gene (DEG) analysis. The univariate Cox analysis of each intersecting DEG and subsequent lasso-based Cox model identified 11 hub survival genes (MYOC, NNAT, MEDAG, TNFSF14, MYH11, NRXN1, P2RY13, CXCR3, IGLV3-25, IGHV1-46, and IGLV2-8). Then, a hub survival gene-based risk score gene signature was constructed; higher risk scores predicted worse SARC prognosis (p < 0.0001). A nomogram including the risk scores, immune/stromal scores and clinical factors showed a good prediction value for SARC overall survival (C-index = 0.716). Finally, connectivity mapping analysis identified that the histone deacetylase inhibitors trichostatin A and vorinostat might have the potential to reverse the harmful TME for patients with SARC.ConclusionThe current study provided new indications for the association between the TME and SARC. Lists of TME related survival genes and potential therapeutic drugs were identified for SARC.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of Tumor Microenvironment-Related Prognostic Genes in Sarcoma

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Several previous studies have revealed that MYH11 is a biomarker of BLCA (15,17), which is consistent with our conclusion. Additionally, the expression level of MYH11 has been reported to be dysregulated in colorectal cancer (33,34), lung cancer (35), laryngeal cancer (36) and acute myeloid leukemia (37). Based on these researches above mentioned, we speculate that myosin-dependent contractile activity in nonmuscle cells may be participated in cell adhesion and migration to promote tumor invasion.…”

Section: Discussionmentioning

confidence: 84%

Identification of Hub Genes Associated With Progression and Prognosis of Bladder Cancer by Integrated Bioinformatics Analysis.

Liu

Sheng

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Bladder cancer (BLCA) is the most popular malignant carcinomas in genitourinary system which has a high incidence and is prone to relapse. However, the molecular mechanism of BLCA remains to be unclear. Moreover, there is still a shortage of effective biomarkers that can predict progression and prognosis of BLCA. The objective of current study is to screen significant genes as biomarkers to forecast the progression and prognosis of BLCA patients.Methods: Gene expression profile downloaded from TCGA database and GEO database was used. Differential gene expression analysis and WGCNA were conducted to identify differential co-expression genes. In addition, GO enrichment analysis and KEGG pathway analysis were used to explore the functions of these genes. Moreover, PPI network, OS and DFS were used to identify survival-related hub genes. Finally, the expression levels of these genes were validated by qRT-PCR and HPA database.Results: About 124 differential co-expression genes were identified. And these genes were mainly enriched in muscle system process and muscle contraction (BP), contractile fiber, myofibril, sarcomere, focal adhesion and cell-substrate junction (CC) and actin binding (MF) in GO enrichment analysis, while enriched in vascular smooth muscle contraction, focal adhesion, cardiac muscle contraction, hypertrophic cardiomyopathy, dilated cardiomyopathy and regulation of actin cytoskeleton in KEGG analysis. Furthermore, five survival-related hub genes (MYH11, ACTA2, CALD1, TPM1, MYLK) were identified via overall OS and DFS. In addition, the expression levels of the five survival-related genes were upregulated with the procession of BLCA, such as grade, stage and TNM stage. Finally, all survival-related hub genes were found to be down-regulated in BLCA via qRT-PCR and HPA database.Conclusions: Our current study verified five new key genes in BLCA, which could help us better understand the pathogenesis of BLCA. And these five hub genes may be involved in the development and progression of BLCA and served as potential biomarkers.

show abstract

“…Evidences for c-FOS overexpression as promoting apoptosis and delaying ovarian cancer progression in preclinical models may be supported by the findings in these clinical specimens [ 19 ]. MYH11 expression has been shown to be downregulated in cancers, and its downregulation corresponds to poor prognosis and survival [ 20 ].…”

Section: Resultsmentioning

confidence: 99%

Integrin-Linked Kinase Is a Novel Therapeutic Target in Ovarian Cancer

Ulm

Redfern

Wilson

et al. 2020

JPM

View full text Add to dashboard Cite

Objective: The objective of this study is to identify and validate novel therapeutic target(s) in ovarian cancer. Background: Development of targeted therapeutics in ovarian cancer has been limited by molecular heterogeneity. Although gene expression datasets are available, most of them lack appropriate pair-matched controls to define the alterations that result in the transformation of normal ovarian cells to cancerous cells. Methods: We used microarray to compare the gene expression of treatment-naïve ovarian cancer tissue samples to pair-matched normal adjacent ovarian tissue from 24 patients. Ingenuity Pathway Analysis (IPA) was used to identify target pathways for further analysis. Integrin-linked kinase (ILK) expression in SKOV3 and OV90 cells was determined using Western blot. ILK was knocked down using CRISPR/Cas9 constructs. Subcutaneous xenograft study to determine the effect of ILK knockdown on tumor growth was performed in NOD SCID gamma mice. Results: Significant upregulation of the ILK pathway was identified in 22 of the 24 cancer specimens, identifying it as a potential player that could contribute to the transformation of normal ovarian cells to cancerous cells. Knockdown of ILK in SKOV3 cells resulted in decreased cell proliferation and tumor growth, and inhibition of downstream kinase, AKT (protein kinase B). These results were further validated using an ILK-1 chemical inhibitor, compound 22. Conclusion: Our initial findings validate ILK as a potential therapeutic target for molecular inhibition in ovarian cancer, which warrants further investigation.

show abstract

Clinical and prognostic significance of MYH11 in lung cancer

Cited by 21 publications

References 39 publications

Identification of Tumor Microenvironment-Related Prognostic Genes in Sarcoma

Identification of Tumor Microenvironment-Related Prognostic Genes in Sarcoma

Identification of Hub Genes Associated With Progression and Prognosis of Bladder Cancer by Integrated Bioinformatics Analysis.

Integrin-Linked Kinase Is a Novel Therapeutic Target in Ovarian Cancer

Contact Info

Product

Resources

About